igg isotype control mpc11 antibody  (Bio X Cell)

Journal: Life Science Alliance

Article Title: APR-246 increases tumor antigenicity independent of p53

doi: 10.26508/lsa.202301999

Figure Lengend Snippet: Mice were immunized according to the schematic in . (A) Mean tumor size overtime of GVAX treatment in combination with anti-CTLA4 antibody (clone 9D9, BioXcell). An isotype antibody was used as a negative control (clone MPC11, BioXcell). (B) Survival of these mice, including post reimplantation with 0.1 million B16 cells at day 112. (C) Total number of tumor-free mice per treatment group (n = 30) when three independent experiments were pooled. (A, B, D, E, F, G, H, I) Individual mouse tumor volumes according to the treatment groups of the representative experiment from (A, B). The data represent mean ± SEM and the P -value is represented as *<0.0332, **<0.0021, ***<0.0002, ****<0.0001. P -value was calculated by two-way ANOVA for tumor growth curves, by log-rank (Mantel–Cox) test for survival curves and by unpaired t test for total number of mice comparison. n = 10, representative of three independent experiments.

Article Snippet: Therapeutic in vivo mAbs anti-CD40 (FGK45) and corresponding IgG isotype control (2A3), anti-CTLA-4 (clone 9D9) or the matched IgG isotype control (MPC11) were purchased from Bio X Cell.

Techniques: Negative Control, Comparison